|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM330527584 |
| 003 |
DE-627 |
| 005 |
20240826231835.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202103258
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1513.xml
|
| 035 |
|
|
|a (DE-627)NLM330527584
|
| 035 |
|
|
|a (NLM)34510559
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kang, Mikyung
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.07.2024
|
| 500 |
|
|
|a Date Revised 26.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Chimeric antigen receptor-T (CAR-T) cell immunotherapy has shown impressive clinical outcomes for hematologic malignancies. However, its broader applications are challenged due to its complex ex vivo cell-manufacturing procedures and low therapeutic efficacy against solid tumors. The limited therapeutic effects are partially due to limited CAR-T cell infiltration to solid tumors and inactivation of CAR-T cells by the immunosuppressive tumor microenvironment. Here, a facile approach is presented to in vivo program macrophages, which can intrinsically penetrate solid tumors, into CAR-M1 macrophages displaying enhanced cancer-directed phagocytosis and anti-tumor activity. In vivo injected nanocomplexes of macrophage-targeting nanocarriers and CAR-interferon-γ-encoding plasmid DNA induce CAR-M1 macrophages that are capable of CAR-mediated cancer phagocytosis, anti-tumor immunomodulation, and inhibition of solid tumor growth. Together, this study describes an off-the-shelf CAR-macrophage therapy that is effective for solid tumors and avoids the complex and costly processes of ex vivo CAR-cell manufacturing
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a CAR-macrophage
|
| 650 |
|
4 |
|a DNA/polymer nanocomplex
|
| 650 |
|
4 |
|a cancer therapy
|
| 650 |
|
4 |
|a cytotoxic T lymphocyte
|
| 650 |
|
4 |
|a in situ transfection
|
| 650 |
|
7 |
|a Receptors, Chimeric Antigen
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Lee, Seong Ho
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kwon, Miji
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Byun, Junho
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Dongyoon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Cheesue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koo, Sagang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kwon, Sung Pil
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Moon, Sangjun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jung, Mungyo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hong, Jihye
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Go, Seokhyeong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Song, Seuk Young
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Choi, Jae Hyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hyeon, Taeghwan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Oh, Yu-Kyoung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Hee Ho
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Byung-Soo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 43 vom: 05. Okt., Seite e2103258
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:43
|g day:05
|g month:10
|g pages:e2103258
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202103258
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 43
|b 05
|c 10
|h e2103258
|